Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.
Proprietary VelociSuite® platforms, including VelocImmune® for human monoclonal antibodies, Veloci-Bi®/Veloci-T® for bispecifics, and the Regeneron Genetics Center® for large-scale human genetics research and target discovery.
Funding History
1
Total raised:$40M
IPO$40MUndisclosed
Opportunities
Major near-term opportunities include the multi-billion dollar expansion of Dupixent into COPD, the launch of odronextamab in competitive lymphomas, and defending the ophthalmology franchise with next-generation VEGF C-D.
Long-term, the Regeneron Genetics Center provides a sustained pipeline engine across high-need therapeutic areas.
Risk Factors
Key risks include high reliance on EYLEA and Dupixent revenues, impending EYLEA patent expiries beginning in 2026, clinical/regulatory setbacks in a dense late-stage pipeline, and intense competition across all core therapeutic areas.
Competitive Landscape
Regeneron competes with large pharma and biotech peers in crowded, high-stakes markets. Its differentiated position is secured by proprietary antibody and genetics platforms that enable rapid, internally-driven pipeline generation and a vertically integrated model that controls costs and speed from discovery to commercialization.
